Relationship of maternal serum resistin and visfatin levels with gestational diabetes mellitus

Gynecological Endocrinology

Volumn 30, Issue 5, 2014, Pages 355-358

  Karatas, Ahmet ^a   Tunçay Işikkent, Nilüfer ^b   Ozlü, Tülay ^a   Demirin, Hilmi ^b  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b DUZCE UNIVERSITY   (Turkey)

Author keywords

Gestational diabetes; Insulin resistance; Resistin; Visfatin

Indexed keywords

HEMOGLOBIN A1C; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; BIPARIETAL DISTANCE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FEMUR; FETUS WEIGHT; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEAD CIRCUMFERENCE; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LARGE FOR GESTATIONAL AGE; MATERNAL SERUM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SECOND TRIMESTER PREGNANCY; BIRTH WEIGHT; BLOOD; GLUCOSE TOLERANCE TEST; LONGITUDINAL STUDY; METABOLISM; NEWBORN; NONPARAMETRIC TEST; PHYSIOLOGY; PREGNANCY;

ADULT; BIRTH WEIGHT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; CYTOKINES; DIABETES, GESTATIONAL; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFANT, NEWBORN; INSULIN RESISTANCE; LONGITUDINAL STUDIES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; RESISTIN; STATISTICS, NONPARAMETRIC;

EID: 84898844884     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.887670     Document Type: Article

References (26)

1. Baptiste-Roberts K, Barone BB, Gary TL. Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review. Am J Med 2009;122:207-14
2. American Diabetes Association. Gestational diabetes mellitus (Position Statement). Diabetes Care 2004;27:88-90
3. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-8
4. Catalano P, Tyzbir ED, Roman NM. Longitudinal changes in insulin release and insulin resistance in non-obese pregnant women. Am J Obstet Gynecol 1991;165:1667-72
5. Kafkasli A. Preterm doǧum. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrikte normal ve sorunlu gebelikler. Istanbul: Nobel & Güneş tip kitabevi; 2009:713-32
6. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006;17:170-5
7. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013;18:12
8. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;18:426-30
9. Chen D, Fang Q, Chai Y, et al. Serum resistin in gestational diabetes mellitus and early postpartum. Clin Endocrinol 2007;67: 208-11
10. Skvarca A, Tomazic M, Krhin B, et al. Adipocytokines and insulin resistance across various degrees of glucose tolerance in pregnancy. J Int Med Res 2012;40:583-9
11. Akdeniz N, Kuyumcuoǧlu U, Kale A, et al. Resistin may not associate with gestational diabetes mellitus although insulin resistance. Clin Exp Obstet Gynecol 2011;38:236-8
12. Rezvan N, Hosseinzadeh-Attar MJ, Masoudkabir F, et al. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy. Arch Gynecol Obstet 2012;285:1257-62
13. Carpenter MW, Coustan DR. Criteria for screening tests forgestational diabetes. Am J Obstet Gynecol 1982;144:768-73
14. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34:S11-61
15. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12
16. Kuzmicki M, Telejko B, Szamatowicz J, et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol 2009;25:258-63
17. Lappas M, Yee K, Permezel M, Rice GE. Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 2005;186:457-65
18. Telejko B, Kuzmicki M, Zonenberg A, et al. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 2009;84:68-75
19. Chan TF, Yuan SS, Chen HS, et al. Correlations between umbilical and maternal serum adiponectin levels and neonatal birthweights. Acta Obstet Gynecol Scand 2004;83:165-9
20. Wang J, Shang LX, Dong X, et al. Relationship of adiponectin and resistin levels in umbilical serum, maternal serum and placenta with neonatal birthweight. Aust N Z J Obstet Gynaecol 2010;50: 432-8
21. Shang LX, Tang QL, Wang J, et al. Relationship of adiponectin and visfatin with fetus intrauterine growth. Zhonghua Fu Chan Ke Za Zhi 2009;44:246-8
22. Mohamed MH, Gad GI, Ibrahim HY, et al. Cord blood resistin and adiponectin in term newborns of diabetic mothers. Arch Med Sci 2010;6:558-66
23. Mazaki-Tovi S, Romero R, Kusanovic JP, et al. Maternal visfatin concentration in normal pregnancy. J Perinat Med 2009; 37:206-17
24. Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033-7
25. Ferreira AF, Rezende JC, Vaikousi E, et al. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 2011;57:609-13
26. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70.